Brief: Vor Biopharma Reports Fourth Quarter Results

Vor Biopharma

23/03/2023 20:11

March 23 (Reuters) - Vor Biopharma Inc  VOR.O :
    * VOR BIO REPORTS FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL
RESULTS AND PROVIDES COMPANY UPDATE
    * $116M FINANCING EXTENDS EXPECTED CASH RUNWAY INTO Q1 2025
    * ADDITIONAL TREM-CEL DATA EXPECTED BY YEAR-END 2023;
VCAR33ALLO
ON TRACK FOR IND SUBMISSION IN FIRST HALF OF 2023
    * VOR BIOPHARMA-INITIAL CLINICAL DATA SUPPORTS FOUNDING
VISION
THAT ENGINEERED HEMATOPOIETIC STEM CELLS CAN ENABLE TREATMENT
OPTIONS AFTER AML TRANSPLANT
    * CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $230.2 MILLION
AS OF
DECEMBER 31, 2022
    * QTRLY LOSS PER SHARE $0.53
    * Q4 EARNINGS PER SHARE VIEW $-0.60 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX89j3pJ 
Further company coverage:  VOR.O 

 ((Reuters.Briefs@thomsonreuters.com;))